Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TERN-501 in Metabolic Dysfunction Associated Steatohepatitis: NCT05415722 Clinical Landscape Report 2026
16 October 2026
NCT05415722 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Armocibart in Hemophilia B: NCT05421429 Clinical Landscape Report 2026
16 October 2026
NCT05421429 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Metabolic Dysfunction Associated Steatohepatitis: NCT05424003 Clinical Landscape Report 2026
16 October 2026
NCT05424003 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tinostamustine in Glioblastoma Multiforme: NCT05432375 Clinical Landscape Report 2026
16 October 2026
NCT05432375 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Glioblastoma Multiforme: NCT05423210 Clinical Landscape Report 2026
16 October 2026
NCT05423210 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT05428150 Clinical Landscape Report 2026
16 October 2026
NCT05428150 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osivelotor in Anemia, Sickle Cell: NCT05431088 Clinical Landscape Report 2026
16 October 2026
NCT05431088 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
C-106 in Idiopathic Pulmonary Fibrosis: NCT05427253 Clinical Landscape Report 2026
16 October 2026
NCT05427253 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Astrocytoma: NCT05429502 Clinical Landscape Report 2026
16 October 2026
NCT05429502 clinical landscape for Astrocytoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma, IDH-Wildtype: NCT05432804 Clinical Landscape Report 2026
16 October 2026
NCT05432804 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Recurrent Glioblastoma: NCT05432518 Clinical Landscape Report 2026
16 October 2026
NCT05432518 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Stroke: NCT05434000 Clinical Landscape Report 2026
16 October 2026
NCT05434000 clinical landscape for Stroke: endpoints, sponsor, phase, geography, readouts, asset context and development white space.